A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants

Additional inclusion and exclusion criteria may apply. Inclusion Criteria: * Seated blood pressure is ≥ 90/40 mmHg and ≤ 140/90 mmHg at the screening visit. * Seated pulse rate is ≥ 40 bpm and ≤ 99 bpm at the screening visit. * QTcF interval is ≤ 460 msec (males) and ≤ 470 msec (females) and has ECG findings considered normal or not clinically significant by the PI or designee at the screening visit. * Liver function test including ALT, AST, ALP and total bilirubin ≤ upper limit of normal at the screening visit. * Estimated CrCL ≥ 80 mL/min at the screening visit. Exclusion Criteria: * Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, respiratory, endocrine, or psychiatric disorder. * History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs (cholecystectomy will not be allowed; uncomplicated appendectomy and hernia repair will be allowed). * Presence of any other condition (including surgery) known to interfere with the absorption, distribution, metabolism, or excretion of medicines. * History or presence of hepatobiliary or thyroid-related disease. * Significant change (approximately 10% increase or decrease) in weight within 3 months prior to first dosing in the opinion of the PI or designee. * History of alcoholism or drug/chemical abuse within 2 years prior to check-in. * Positive results for HIV, HBsAg, or HCV at the screening visit. * Poor peripheral venous access.